Thomas Shrader • BTIG, LLC

Answer

CEO Mark Baum clarified that ApolloCare's value is its broader network of contracted insurance plans, which helps capture more commercially covered prescriptions and supports a higher overall ASP. He explained that 'IHEZO for all' is not about free drug trials but about building 'reimbursement confidence' by educating physicians on the product's pervasive insurance coverage to drive deeper utilization.

Ask Fintool Equity Research AI

Answer

CEO John Jacobs responded that the CIC study is designed to show an immune response, not to meet a specific reactogenicity target, though they expect it to be reasonable. COO John Trizzino clarified that the BLA filing is for the existing vaccine based on prior Phase III data, and an updated strain would be a subsequent filing post-approval.

Ask Fintool Equity Research AI

Answer

Chief Commercial Officer Christopher Martin explained that Verona is not significantly affected by the Part D redesign, as approximately 80% of reimbursement is through the medical benefit (Part B or Medicare Advantage). Chief Development Officer Dr. Tara Rheault and Chief Medical Officer Dr. Kathleen Rickard added that while few patients with confirmed bronchiectasis were in the ENHANCE trials, the drug's mechanisms are applicable. They noted that while there is symptom overlap, the underlying diseases differ, and about 20% of diagnosed bronchiectasis patients may also have COPD.

Ask Fintool Equity Research AI

Answer

Christopher Martin, Chief Commercial Officer, clarified that Ohtuvayre is primarily reimbursed under medical benefit (Part B), making the Part D redesign impact minimal. Dr. Tara Rheault, Chief Development Officer, and Dr. Kathleen Rickard, Chief Medical Officer, explained that while few patients with confirmed bronchiectasis were in the pivotal trials, the drug's mechanisms are applicable. They noted an estimated 20% of bronchiectasis patients also have a COPD diagnosis.

Ask Fintool Equity Research AI

Answer

Chief Commercial Officer Chris Martin explained that the prescribing pattern reflects typical launch dynamics of early versus late adopters, rather than a specific structural issue. He noted that market research indicates non-prescribing physicians see the drug's benefits and intend to prescribe it in the future. Regarding the delivery method, he asserted that innovation is trumping the route of administration, calling the nebulizer a 'nonissue' and noting that some patients find it a comforting way to receive their medication.

Ask Fintool Equity Research AI

Answer

Executive David Zaccardelli and Chief Commercial Officer Chris Martin explained that physicians typically accelerate usage after positive initial patient feedback, which is encouraged by increased interaction with the sales team. Martin confirmed the support infrastructure is working well, with a significant majority of scripts being paid and over 80% of dispensed patients having a co-pay under $10.

Ask Fintool Equity Research AI

Answer

Chief Commercial Officer Chris Martin explained it's too early for a detailed patient profile analysis but confirmed the initial prescribers are from their top-tier target list of physicians. These doctors report a high unmet need for patients with persistent symptoms. An unnamed executive clarified that developing a fixed-dose combination typically requires working through the monotherapy's development in that specific formulation first.

Ask Fintool Equity Research AI

Answer

An unnamed executive responded that the patient attrition rate is currently running slightly below their plan, indicating better-than-expected retention. He also confirmed that the company is not making any adjustments to the trial's sample size.

Ask Fintool Equity Research AI